| Abstrakt: |
A recent study conducted at University Hospital in Munich, Germany, compared the efficacy and safety of two first-line therapies for hepatocellular carcinoma (HCC), atezolizumab/bevacizumab and lenvatinib. The study focused on the risk of bleeding and thromboembolic events associated with these therapies. The researchers analyzed data from 464 patients and found that the incidence of bleeding and thromboembolic events did not significantly differ between the two treatment groups. Therefore, the study suggests that safety considerations related to these events may not be helpful in guiding clinical decision-making when choosing between atezolizumab/bevacizumab and lenvatinib for HCC treatment. [Extracted from the article] |
